Bicara Therapeutics Inc
BCAX
NASDAQ
Biotechnology
$24.28
USD
+0.65 (+2.75%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $1.82B
Volume 479.9K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-185.36M
TTM
-80.5%
YoY
Operating Cash Flow
$-134.85M
TTM
-33.6%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 7.2 | 7.7 | 8.1 | 12.7 | 14.2 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 32.0 | 40.7 | 41.1 | 60.2 | 60.0 |
Operating Income | -32.0 | -40.7 | -41.1 | -60.2 | -60.0 |
EBITDA | -32.0 | -40.7 | -41.1 | -60.2 | -59.9 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 4.7 | 4.4 | 3.8 | 4.1 | 4.6 |
Income Before Income Taxes | -27.3 | -36.3 | -37.3 | -56.2 | -55.4 |
Income Taxes | 0.1 | 0.0 | 0.1 | 0.1 | 0.1 |
Net Income | -27.4 | -36.3 | -37.4 | -56.2 | -55.4 |
Consolidated Net Income / Loss | -27.4 | -36.3 | -37.4 | -56.2 | -55.4 |
Net Income Attributable to Common Shareholders | -27.4 | -36.3 | -37.4 | -56.2 | -55.4 |
Basic EPS | -$0.50 | -$0.67 | -$0.68 | -$0.93 | -$0.82 |
Diluted EPS | -$0.50 | -$0.67 | -$0.68 | -$0.93 | -$0.82 |
Basic Shares Outstanding | 54.5M | 54.6M | 55.1M | 60.7M | 67.9M |
Diluted Shares Outstanding | 54.5M | 54.6M | 55.1M | 60.7M | 67.9M |